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Abstract
Background: In the present study, by comparing the responses in wild-type mice (WT) and mice
lacking (KO) the inducible (or type 2) nitric oxide synthase (iNOS), we investigated the role played
by iNOS in the development of on the lung injury caused by bleomycin administration. When
compared to bleomycin-treated iNOSWT mice, iNOSKO mice, which had received bleomycin,
exhibited a reduced degree of the (i) lost of body weight, (ii) mortality rate, (iii) infiltration of the
lung with polymorphonuclear neutrophils (MPO activity), (iv) edema formation, (v) histological
evidence of lung injury, (vi) lung collagen deposition and (vii) lung Transforming Growth Factor
beta1 (TGF-β 1) expression.
Methods: Mice subjected to intratracheal administration of bleomycin developed a significant lung
injury. Immunohistochemical analysis for nitrotyrosine revealed a positive staining in lungs from
bleomycin-treated iNOSWT mice.
Results: The intensity and degree of nitrotyrosine staining was markedly reduced in tissue section
from bleomycin-iNOSKO mice. Treatment of iNOSWT mice with of GW274150, a novel, potent
and selective inhibitor of iNOS activity (5 mg/kg i.p.) also significantly attenuated all of the above
indicators of lung damage and inflammation.
Conclusion: Taken together, our results clearly demonstrate that iNOS plays an important role
in the lung injury induced by bleomycin in the mice.
Background
Pulmonary fibrosis is a progressive interstitial lung disease
of unknown etiology. Pulmonary fibrosis is characterized
by inflammatory cell infiltration, fibroblast proliferation,
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and excessive deposition of extracellular matrix proteins
in the lung parenchyma [1,2]. The disease most com-
monly affects middle-age adults, although infants and
children are also affected. Various studies have also indi-
cated that the treatment with bleomycin during cancer
chemotherapy in humans also induces interstitial fibrosis
[3,4].
Nitric oxide (NO) is a pleiotropic mediator, which acts in
a variety of physiological and pathophysiological proc-
esses [5-8]. NO is produced from the oxidation of L-
arginine by the enzyme NO synthase [9,10] which occurs
in three major isoforms; two are constitutive (endothelial
and neuronal, indicated with cNOS), and one is inducible
(macrophagic). The constitutively expressed enzyme
(cNOS) are calcium-dependent, release NO under physio-
logical condition in various cells, including endothelial
cells and neurons, and NO released by these isoform are
involved in the regulation of blood pressure in organ
blood flow distribution, in the inhibition of the adhesion
and activation of platelets and polymorphonuclear gran-
ulocytes and in neuronal transmission. The inducible iso-
form of NOS (iNOS) is calcium-independent and can be
induced by proinflammatory agents, such as endotoxins
(bacterial lipopolysaccharide, LPS), interleukin-1β , tumor
necrosis factor-α  (TNF-α ) and interferon-γ  (INF-γ ), in
endothelial and smooth-muscle cells, in macrophages
and in other cell types [5-9]. Enhanced formation of NO
following the induction of iNOS has been implicated in
the pathogenesis of shock and inflammation [5].
Although the severity and duration of inflammation may
dictate the timing and extent of NOS expression, it is now
evident that the up-regulation of NOS can modulate
inflammation [9-11]. Pharmacological inhibition of
iNOS or genetic inactivation of NOS (iNOS knockout
mice) attenuates the activation of the transcription factors
nuclear factor kappa B (NF-κ B) and signal transducer and
activator of transcription-3 (STAT-3), and increases Gran-
ulocyte Colony-Stimulating Factor (G-CSF) messenger
RNA levels in the tissue. Thus, induced nitric oxide, in
addition to being a "final common mediator" of inflam-
mation, is essential for the up-regulation of the inflamma-
tory response. Furthermore, it has been recently suggested
that some of the cytotoxic effects of NO are tightly related
to the production of peroxynitrite, a high-energy oxidant
deriving by the rapid reaction of NO with superoxide [12-
14]. The resulting oxidative stress may cause cell death
and tissue damage that characterize a number of human
disease states like neurological disorders and stroke,
inflammatory bowel disease, arthritis, toxic shock and
acute reperfusion injuries [15-18]. Thus peroxynitrite, and
not NO, has been proposed to be the ultimate cytotoxic
species in many conditions acting through some mecha-
nisms including the initiation of lipid peroxidation, the
inactivation of a variety of enzymes (e.g. MnSOD) and the
depletion of glutatione. Moreover, peroxynitrite is also
able to induce DNA damage [19,20] resulting in inactiva-
tion of the nuclear enzyme PARS, in depletion of nicoti-
namide adenine dinucleotide (NAD+) and adenosine
triphosphate (ATP) and lastly in cell death [21]. The real-
ization of the cytotoxic potential of NO and peroxynitrite
made it important to seek for pharmacological
approaches, in order to neutralize NO and peroxynitrite-
induced damage by inhibiting iNOS. The role of iNOS in
pathologic condition have induced the development of
selective iNOS inhibitors like GW274150 [(S)-2-Amino-
(1-iminoethylamino)-5-thioheptanoic acid]. This mole-
cule is a novel NOS-inhibitor (sulphur-substituted aceta-
mine amono acid), which acts in competition with L-
arginine and has a very high degree of selectivity for iNOS
when compared to either eNOS (> 300-fold) or nNOS (>
100-fold) [22]. In addition GW274150 is a long acting (5
hours half life in rats) iNOS inhibitor and is also able to
inhibit LPS-mediated increase in plasma NO2
- NO3
- levels
14 h after single intraperitoneal dose (ED50 3 mg kg-1)
[23]. The inhibition of iNOS activity caused by
GW274150 is NADPH-dependent and develops very
slowly, but is rapidly reversible and recent studies reports
the role of this iNOS selective inhibitors in reducing organ
injury in hemorrhagic shock, in collagen induced arthritis
and in renal ischemia/reperfusion [24-26]. In addition
recently we have demonstrated that GW274150 treatment
significantly reduced acute lung injury in an experimental
model of carrageenan induced pleurisy [27]. Therefore the
aim of this study was to investigate the role of iNOS in a
model of lung injury induced by bleomycin administra-
tion using iNOSKO mice and iNOSWT mice. In addition,
we have investigated the effects of the systemic adminis-
tration of GW274150 in iNOSWT mice subjected to bleo-
mycin-induced lung injury. In particular, we have
investigated the effect of the genetic or pharmacological
inhibition of iNOS on the bleomycin induced (i) loss of
body weight, (ii) PMN lung infiltration [myeloperoxidase
(MPO) activity], (iii) lung tissue edema [wet/dry ratio],
(iv) lipid peroxidation, (v) the nitration of tyrosine resi-
dues (an indicator of the formation of peroxynitrite), (vi)
lung damage (histology), (vii) lung collagen deposition
and (viii) lung TGF-β 1 expression.
Materials and methods
Animals
Male CD mice (25–35 g; Harlan Nossan; Italy) were
housed in a controlled environment and provided with
standard rodent chow and water. Animal care was in com-
pliance with Italian regulations on protection of animals
used for experimental and other scientific purpose (D.M.
116192) as well as with the EEC regulations (O.J. of E.C.
L 358/1 12/18/1986).Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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Experimental groups
Mice were randomly allocated into the following groups:
(i) iNOSWT + BLEO group. Mice were subjected to bleo-
mycin-induced lung injury (N = 30), (ii) iNOSKO + BLEO
group. Mice were subjected to bleomycin-induced lung
injury (N = 30), (iii) iNOSWT +saline group. Sham-oper-
ated group in which identical surgical procedures to the
BLEO group was performed, except that the saline was
administered instead of bleomycin, (iv) iNOSKO+saline
group. Identical to iNOSWT +saline group, except for the
use of iNOSKO mice. GW274150 group. Same as the
iNOSWT + BLEO group but iNOSWT mice were adminis-
tered with GW274150 (5 mg/kg) i.p. bolus 30 min after
the administration of BLEO and every 24 h starting from
day 1 (N = 30), (v) Sham+ GW274150 group. Identical to
iNOSWT +saline group, except for the administration of
GW274150 (5 mg/kg) i.p. bolus 30 min after the admin-
istration of BLEO and every 24 h starting from day 1 (N =
30). In another sets of studies, following bleomycin
administration, the various groups of mice (N = 20 for
each group) were observed for 15 days in order to deter-
mine survival differences. The dose of GW274150 used
here has previously been reported by us to reduce the tis-
sue injury caused by inflammation [26].
Induction of lung injury by bleomycin
Mice received a single intratracheal instillation of saline
(0.9%) or saline containing bleomycin sulphate (1 mg/kg
body weight) in a volume of 50 µl and were killed after 15
days by pentobarbitone overdose.
Measurement of fluid content in lung
The wet lung weight was measured after careful excision of
extraneous tissues. The lung was exposed for 48 h at
180°C and the dry weight was measured. Water content
was calculated by subtracting dry weight from wet weight.
Histological examination
Lung biopsies were taken 15 days after injection of bleo-
mycin. Lung biopsies were fixed for 1 week in 10% (w/v)
PBS-buffered formaldehyde solution at room tempera-
ture, dehydrated using graded ethanol and embedded in
Paraplast (Sherwood Medical, Mahwah, NJ, USA). After
embedding in paraffin, the sections were prepared and
stained by H&E or by trichrome stain. All sections were
studied using light microscopy (Dialux 22 Leitz). The
severity of fibrosis was semi quantitatively assessed
according to the method proposed by Ashcroft and co-
workers [28]. Briefly, the grade of lung fibrosis was scored
on a scale from 0 to 8 by examining section randomly
chosen fields per sample at a magnification of ×100. Cri-
teria for grading lung fibrosis were as follows: grade 0,
normal lung; grade 1, minimal fibrous thickening of alve-
olar or bronchiolar walls; grade 3, moderate thickening of
walls without obvious damage to lung architecture; grade
5, increased fibrosis with definite damage to lung struc-
ture and formation of fibrous bands or small fibrous
masses; grade 7, severe distortion of structure and large
fibrous areas; grade 8, total fibrous obliteration of fields.
Collagen Protein Measurement
Total lung collagen content was measured by means of
Sircol Soluble Collagen Assay (Biocolor, Newtownabbey,
Northern Ireland), an assay based on a modification of
the sirius red method, as recommended by the manufac-
turer. Briefly, after the sacrifice, mice lungs were explanted
and homogenized. Samples were then incubated at 4°C
for 2 h and centrifuged at 15,000 × g. Supernatants (20 µl)
were diluted 5 times in lysis buffer, added to 1 mL of Sir-
col Dye Reagent and then mixed for 30 minutes at room
temperature in a mechanical shaker. The collagen-dye
complex was precipitated by centrifugation at 10000 × g
for 10 min. The unbound dye solution was then carefully
removed. The precipitated complex was resuspended in 1
mL of alkali reagent. The obtained solution was finally
placed in a 96 wells flat bottomed plate and evaluated in
a plate reader (absorbance = 540 nm). Obtained values
were then compared to the standard curve as recom-
mended to obtain absolute collagen content. Shown data
represent the mean collagen content, expressed as µg/µl of
lung homogenates (± SE), of at least 4 independent
experiments.
Immunohistochemical localization of nitrotyrosine
Tyrosine nitration, an index of the nitrosylation of pro-
teins by peroxynitrite and/or ROS, was determined by
immunohistochemistry as previously described [29]. At
the end of the experiment, the tissues were fixed in 10%
(w/v) PBS-buffered formaldehyde and 8 µm sections were
prepared from paraffin embedded tissues. After deparaffi-
nization, endogenous peroxidase was quenched with
0.3% (v/v) hydrogen peroxide in 60% (v/v) methanol for
30 min. The sections were permeablized with 0.1% (w/v)
Triton X-100 in PBS for 20 min. Non-specific adsorption
was minimized by incubating the section in 2% (v/v) nor-
mal goat serum in PBS for 20 min. Endogenous biotin or
avidin binding sites were blocked by sequential incuba-
tion for 15 min with biotin and avidin (DBA, Milan,
Italy), respectively. Sections were incubated overnight
with anti-nitrotyrosine polyclonal antibody (1:500 in
PBS, v/v). Sections were washed with PBS, and incubated
with secondary antibody. Specific labeling was detected
with a biotin-conjugated goat anti-rabbit IgG and avidin-
biotin peroxidase complex (DBA, Milan, Italy). In order to
confirm that the immunoreactions for the nitrotyrosine
were specific some sections were also incubated with the
primary antibody (anti-nitrotyrosine) in the presence of
excess nitrotyrosine (10 mM) to verify the binding specif-
icity. In this situation no positive staining was found inRespiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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the sections indicating that the immunoreactions were
positive in all the experiments carried out.
Myeloperoxidase activity
Myeloperoxidase (MPO) activity, an indicator of poly-
morphonuclear leukocyte (PMN) accumulation, was
determined as previously described [30]. At the specified
time following injection of bleomycin, lung tissues were
obtained and weighed, each piece homogenized in a solu-
tion containing 0.5% (w/v) hexadecyltrimethyl-ammo-
nium bromide dissolved in 10 mM potassium phosphate
buffer (pH 7) and centrifuged for 30 min at 20,000 × g at
4°C. An aliquot of the supernatant was then allowed to
react with a solution of tetramethylbenzidine (1.6 mM)
and 0.1 mM hydrogen peroxide. The rate of change in
absorbance was measured spectrophotometrically at 650
nm. MPO activity was defined as the quantity of enzyme
degrading 1 µmol of peroxide/min at 37°C and was
expressed in milliunits per g of wet tissue.
Thiobarbituric acid-reactant substances measurement
Thiobarbituric acid-reactant substances measurement,
which is considered a good indicator of lipid peroxida-
tion, was determined, as previously described [27], in the
lung tissues. At the specified time following injection of
bleomycin lung tissues were homogenized in 1.15% KCl
solution. An aliquot (100 µl) of the homogenate was
added to a reaction mixture containing 200 µl of 8.1%
SDS, 1500 µl of 20% acetic acid (pH 3.5), 1500 µl of 0.8%
thiobarbituric acid and 700 µl distilled water. Samples
were then boiled for 1 h at 95°C and centrifuged at 3,000
× g for 10 min. The optical density at 650 nm (OD650) was
measured using ELISA microplate reader (SLT- Labinstru-
ments Salzburg, Austria). Thiobarbituric acid-reactant
substances were calculated by comparison with OD650 of
standard solutions of 1,1,3,3-tetramethoxypropan 99%
malondialdehyde bis (dymethyl acetal) 99% (Sigma,
Milan). The absorbance of the supernatant was measured
by spectrophotometry at 650 nm.
Bronchoalveolar Lavage (BAL)
Seven days after bleomycin or saline solution instillation,
mice were euthanized and the trachea was immediately
cannulated with an I.V. polyethylene catheter (Neo Delta
Ven 2, delta Med, Viadana, Italy) equipped with a 24-
gauge needle on a 1 mL syringe. Lungs were lavaged once
with 0.5 ml D-PBS (GIBCO, Paisley, U.K.). In >95% of the
mice, the recovery volume was over 0.4 ml. The BAL fluid
was spun at 800 rpm, the supernatant was removed and
the pelleted cells were collected. Total BAL cells were enu-
merated by counting on a hemocytometer in the presence
of trypan blue. Cytospins were prepared from resus-
pended BAL cells.
Cytospins of BAL cells were made by centrifuging 50,000
cells onto microscope slides using a Shandon Cytospin 3
(Shandon, Astmoore, U.K.). Slides were allowed to air dry
and were then stained with Diff-Quick Stain Set (Diff-
Quick; Baxter Scientific, Miami, FL). A total of 400 cells
were counted from randomly chosen high power micro-
scope fields for each sample. The differential percentage
was multiplied by the total leukocyte number per mL to
derive the absolute number of monocyte/macrophages,
neutrophils, lymphocytes and eosinophils.
TGF-β 1 western blot analysis
Immediately after sacrifice, lungs were removed, thor-
oughly washed, frozen and stored at -80°C until protein
extraction. Thawed tissues were washed in PBS and
homogenized with an Ultra-Turrax T25 tissue grinder in
400 µl of 10 mM cold Tris homogenization buffer con-
taining 5 mM EDTA, 1% Tryton-X100, 1 mM phenyl-
methylsulfonylfluoride, 25 µg/ml leupeptin and 0.5%
aprotinin (all from Sigma-Aldrich). After homogeniza-
tion, samples were incubated at 4°C for 2 h, centrifuged
for 10 min at 15,000 × g and the supernatant was proc-
essed for protein concentration according to the method
of Bradford [31]. Samples were diluted in sample buffer
and boiled for 5 min. Electrophoresis was performed in
15% sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (40 mA/h) using 60–80 µg of cell proteins
per lane. After separation, proteins were transferred onto
a nitrocellulose membrane (Hybond ECL, Amersham Bio-
sciences Europe GmbH, Milan, Italy) for 2 h at room tem-
perature using a transblot semidry transfer cell. After
blocking, the membranes were incubated with a mono-
clonal mouse anti-TGF-β 1 (0.8 µg/ml; Chemicon, Temec-
ula, CA) overnight at 4 °C. Membranes were then
thoroughly washed and incubated with HRP-conjugated
secondary antibody. Specific bands were visualized using
the SuperSignal chemiluminescent detection system
(Pierce Biotechnology Inc., Rockford, IL). The same mem-
branes were washed with a stripping solution containing
0.2 M glycine, 0.1% SDS, 1% Tween-20 and re-blotted
with mouse anti-β -actin (1:250; Sigma-Aldrich) overnight
at 4°C and processed for signal detection as described
above.
TGF-β 1 expression was normalized for β -actin and data
are expressed as the percent increase of TGF-β 1 expression
in bleomycin-treated mice vs. control animals.
Materials
Unless otherwise stated, all compounds were obtained
from Sigma-Aldrich Company Ltd. (Poole, Dorset, U.K.).
All other chemicals were of the highest commercial grade
available. All stock solutions were prepared in non-pyro-
genic saline (0.9% NaCl; Baxter, Italy, UK).Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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Statistical evaluation
All values in the figures and text are expressed as mean ±
standard error of the mean (SEM) of N observations. For
the in vivo studies N represents the number of animals
studied. In the experiments involving histology or immu-
nohistochemistry, the figures shown are representative of
at least three experiments performed on different experi-
mental days. The results were analyzed by one-way
ANOVA followed by a Bonferroni post-hoc test for multiple
comparisons. A P-value of less than 0.05 was considered
significant. Statistical analysis for survival data was calcu-
lated by Fisher's exact probability test. For such analyses,
p < 0.05 was considered significant. Mann-Withney U test
was used to compare the percent increase of TGF-β 1 in
iNOS-/- and GW274150-treated animals versus iNOS wild
type mice; a p < 0.05 was considered significant.
Results
The development of bleomycin-induced lung injury is 
attenuated in iNOSKO mice
Histological examination of lung sections revealed signif-
icant tissue damage (Fig 1B,B1 Table 1). Thus, when com-
pared to lung sections taken from saline-treated animals
(Fig. 1A,A1 Table 1), histological examination of lung sec-
tions of iNOSWT mice treated with bleomycin character-
ized by extensive inflammatory infiltration by
neutrophils, lymphocyte and plasma cells extending
through the lung epithelial (Fig. 1B,B1 Table 1), fibrosis
(Fig. 1B1 Table 1) and granulomas in perivascular region
(Fig. 1B1). The absence or inhibition of iNOS in mice
(animals with the iNOSKO phenotype or iNOSWT mice
treated with GW274150) significantly prevented lung
inflammation induced by bleomycin administration (Fig.
1C,C1, D,D1 respectively). Furthermore, the injection of
bleomycin in iNOSWT mice elicited an inflammatory
response characterized by the accumulation of water in
lung as an indicator of fluid content, (Fig. 2) and neu-
trophils infiltration in the lung tissues (Fig. 3). The
absence or inhibition of iNOS in mice (animals with the
iNOSKO phenotype or iNOSWT mice treated with
GW274150) significantly reduced the fluid content and
the neuthrophil infiltration (Figs. 2, 3).
iNOSKO and GW274150 treated mice show a reduced 
collagen production in response to bleomycin
iNOSWT mice exposed to bleomycin showed a significant
increase of lung collagen content after 7 days if compared
to sham mice: from 1.23 ± 0.39 µg/µl to 3.62 ± 0.33 µg/
µl, p < 0.001. iNOSKO and GW274150 treated iNOSWT
mice that underwent bleomycin tracheal instillation did
not show such an increase of lung collagen content (Fig
4). These animals, when exposed to bleomycin, showed a
reduced collagen lung deposition if compared to iNOSWT
mice: 0.94 ± 0.12 and 2.18 ± 0.17 µg/µl vs. 3.62 ± 0.33 µg/
µl, (p < 0.001 and p < 0.01 respectively, Fig. 4)
Nitrotyrosine formation and lipid peroxidation
Immunohistochemical analysis of lung sections obtained
from bleomycin-treated iNOSWT mice revealed a positive
staining for iNOS manly localized in plasma cell and lym-
phocytes (Fig. 5B). In contrast, no staining for iNOS was
found in the lungs of bleomycin-treated iNOSKO mice
(Fig. 5C) and in the lung from bleomycin-injected
iNOSWT mice treated with GW274150 (Fig. 5D). Staining
was absent in lung tissue obtained from the sham group
(Fig. 5A). All iNOSWT mice, who were treated with bleo-
mycin, exhibited a substantial increase in the lung thio-
barbituric acid-reactant substances levels (index of lipid
peroxidation) (Fig. 6). The absence or inhibition of iNOS
in mice (animals with the iNOSKO phenotype or
iNOSWT mice treated with GW274150) significantly
attenuate the increase in thiobarbituric acid-reactant sub-
stances lung levels caused by bleomycin in the lung (Fig.
6). There was no increase in lung thiobarbituric acid-reac-
tant substances level in sham-operated animals (Fig 6).
Effect of INOS inhibition on the on changes of body weight 
and survival rate
In iNOSWT mice, the severe lung injury caused by bleo-
mycin administration was associated with a significant
loss in body weight (Fig. 7). The absence or inhibition of
iNOS in mice (animals with the iNOSKO phenotype or
iNOSWT mice treated with GW274150) significantly
attenuate the loss in body weight (Fig. 7). The survival of
animals was monitored for 15 days. Bleomycin-treated
iNOSWT mice developed severe lung injury and 60% of
these animals died within 15 days after bleomycin admin-
istration (Fig 8). In contrast, none of the iNOSKO mice as
well as the iNOSWT which had been treated with
GW274150 died (Fig. 8).
Bronchoalveolar Lavage
Instillation of saline solution produced no significant
increase in leukocyte numbers in BAL fluid of iNOSKO
and GW274150 treated iNOSWT mice compared to the
sham wild type group (2.48 ± 0.45 and 1.77 ± 0.24 vs.
1.69 ± 0.37 cells × 105/mL ± SE). Bleomycin instillation in
iNOSWT mice produced a significant increase of inflam-
matory cells compared to sham iNOSWT mice (8.93 ±
0.53 vs 1.69 ± 0.37 cells × 105/mL ± SE, p < 0.001) (Fig.
9). iNOSKO and GW274150 treated iNOSWT mice that
underwent to bleomycin tracheal instillation did not
show such an increase of BAL total cellularity as compared
to bleomycin iNOSWT mice group (2.05 ± 0.35 and 2.83
± 0.41 vs. 8.92 ± 0.53 cells × 105/mL ± SE, p < 0.001). Dif-
ferential cell counts showed a similar profile across all of
the sham groups. In bleomycin treated iNOSWT mice it
was evident an increase of monocytes (6.48 ± 0.39 vs. 1.57
± 0.36 cells × 105/mL ± SE, p < 0.001), lymphocytes (1.49
± 0.20 vs. 0.19 ± 0.08 cells × 105/mL ± SE, p < 0.001) and
neutrophils (0.94 ± 0.20 vs. 0.10 ± 0.04 cells × 105/mL ±Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
Page 6 of 17
(page number not for citation purposes)
Effect of iNOS inhibition on lung injury Figure 1
Effect of iNOS inhibition on lung injury. H&E stain: × 250. A: Saline control, normal lung architecture. B: Bleomycin alone 
in iNOSWT mice, extensive inflammation with inflammatory cells infiltration and fibrosis. C: Bleomycin in iNOSKO mice 
patchy areas of inflammation with minimal fibrosis. D: Bleomycin in iNOSWT mice plus GW274150 patchy areas of inflamma-
tion with minimal fibrosis. Comparable sections of mouse lung stained with trichrome: A1: saline control: normal lung archi-
tecture; B1; Bleomycin alone in iNOSWT mice, extensive areas of collagen; C1: Bleomycin in iNOSKO mice minimal collagen; 
D1: Bleomycin in iNOSWT mice plus GW274150 minimal collagen. Figure is representative of at least 3 experiments per-
formed on different experimental days.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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Table 1: Histological Scoring of lung fibrosis
SHAM + vehicle Bleomycin + iNOSWT Bleomycin + iNOSKO Bleomycin + iNOSWT 
+ GW274150
Lung fibrosis score ND 5.1 ± 0.11* 1.5 ± 0.08° 1.4 ± 0.10°
The above parameters were evaluated at 15 days after bleomycin administration. *p < 0.01 versus sham. °p < 0.01 represents significant reduction 
of the various parameters in the group in which iNOS was inhibited or absent.
Effect of genetic or pharmacological inhibition of iNOS on edema in the lung Figure 2
Effect of genetic or pharmacological inhibition of iNOS on edema in the lung. The injection of bleomycin in 
iNOSWT mice elicited an inflammatory response characterized by the accumulation of water in lung as an indicator of edema. 
The genetic or pharmacological inhibition of iNOS significantly reduced the edema formation. Data are means ± s.e. means 
from 10 mice for each group. *p < 0.01 versus sham. °p < 0.01 represents significant reduction of the various parameters in the 
group in which iNOS was inhibited or absent.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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SE, p < 0.001) if compared to sham wild type mice.
iNOSKO and GW274150 treated iNOSWT mice that
underwent to bleomycin tracheal instillation did not
show any increase of BAL inflammatory cells (Fig. 9). In
these mice monocytes (1.55 ± 0.31 and 2.40 ± 0.41 vs.
6.48 ± 0.39 cells × 105/mL ± SE, p < 0.001), lymphocytes
(0.11 ± 0.03 and 0.27 ± 0.1 vs. 1.49 ± 0.2 cells × 105/mL
± SE, p < 0.001) and neutrophils (0.38 ± 0.18 and 0.16 ±
0.07 vs. 0.94 ± 0.20 cells × 105/mL ± SE, p < 0.05 and p <
0.001 respectively) were significantly reduced compared
to bleomycin treated iNOSWT group (Fig. 9). Eosinophils
did not show any statistically significant difference among
all groups.
TGF-β 1 western blot analysis
TGF-β 1 was expressed in all sham groups undergoing
intra-tracheal saline instillation as detected by western
blot analysis (data not shown). Exposure of iNOSWT
mice to bleomycin produced a remarkable increase of
TGF-β 1 expression (247.9 + 34% of control). In contrast,
iNOSKO and GW274150-treated iNOSWT mice subjected
to intra-tracheal bleomycin instillation exhibited only a
slight increase of TGF-β 1 expression, 129.4 ± + 21.4% and
120.1 ± 19.4% for iNOSKO and GW274150-treated
iNOSWT mice, respectively, that yielded statistical signifi-
cance when compared to iNOSWT (p < 0.05 and p <
0.001) (Fig. 10).
Effect of genetic or pharmacological inhibition of iNOS on myeloperoxidase activity in the lung Figure 3
Effect of genetic or pharmacological inhibition of iNOS on myeloperoxidase activity in the lung. Myeloperoxidase 
(MPO) activity in the lungs of bleomycin-treated iNOSWT mice were significantly increased in comparison to sham-operated 
mice. The genetic or pharmacological inhibition of iNOS significantly reduced the bleomycin-induced increase in MPO activity. 
Data are means ± s.e. means from 10 mice for each group. *p < 0.01 versus sham. °p < 0.01 represents significant reduction of 
the various parameters in the group in which iNOS was inhibited or absent.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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Discussion
Pulmonary fibrosis is a common response to various
insults to the lung and it is the end-point of a numerous
and heterogeneous group of disorders known as
interstitial lung diseases (ILD) that are characterized by
chronic inflammation and progressive fibrosis of the pul-
monary interstitium: alveolar walls (including epithelial
cells and capillaries), septae, and the perivascular, peril-
ymphatic, and peribronchiolar connective tissues [32].
While the pathogenesis is incompletely understood, a
growing body of evidence suggests two different patho-
genic routes for developing pulmonary fibrosis. The
inflammatory pathway, where a shift to the so-called T-
helper 2 type cytokine networks is critical, and the epithe-
lial pathway represented by idiopathic pulmonary fibro-
sis, by far the most aggressive ILD. Both routes may trigger
a number of cytokines/growth factors inducing fibroblast
migration/proliferation and phenotype change to myofi-
broblasts, with a consequent accumulation of extracellu-
lar matrix [33]. In addition, various evidences have point
out an important role for IL-6 and IL-11 in the pulmonary
fibrosis [34,35].
The common pathologic features in ILD, include the
fibrosis of the interstitium, involve collagen, elastic and
smooth muscle elements, architectural remodeling and
chronic inflammation of the interstitium (ie, variable
increases in lymphocytes, neutrophils, plasma cells, mac-
rophages, eosinophils, and mast cells), hyperplasia of
type II cells and hyperplasia of endothelial cells [32].
Data represent the mean collagen content, expressed as µg/µl of lung homogenates (+/- SE), of at least 4 independent  experiments Figure 4
Data represent the mean collagen content, expressed as µg/µl of lung homogenates (+/- SE), of at least 4 inde-
pendent experiments. *p < 0.01 versus sham. °p < 0.01 represents significant reduction of the various parameters in the 
group in which iNOS was inhibited or absent.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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Intratracheal instillation of the antitumour agent BLM is
the most commonly used animal model for pulmonary
fibrosis [36]. The bleomycin-oxygen complex is thought
to bind to DNA and lead to the efficient cleavage of the
phosphodiester-deoxyribose backbone and the genera-
tion of ROS [37] In the presence of oxygen and a reducing
agent in fact, the ferrous ion-BLM complex becomes acti-
vated and functions mechanically as a ferrous oxidase,
transferring electrons from ferrous ion to molecular oxy-
gen to produce ROS that cause scission of DNA [38,39].
Therefore, earlier reports [40,41] point out that the patho-
genesis of BLM-induced fibrosis, at least in part, is medi-
ated through the generation of reactive oxygen species
(ROS) which cause the peroxidation of membrane lipids
and DNA damage. If, that perspective is true, then antioxi-
dant therapy may prevent the lung fibrosis caused by BLM
and may prevent other diseases related with interstitial
pulmonary fibrosis. Because BLM administration results
in increased lipid peroxidation (LPO) and alters activities
of antioxidant enzymes in bronchoalveolar lavage fluids
(BALFs) and lung tissue [42,43], in previous studies
[44,45] some natural or synthetic antioxidants have been
used to protect against BLM oxidative lung toxicity both in
vivo and also in vitro. In addition to ROS, an overproduc-
tion of nitric oxide (NO) due to the expression of the
inducible isoform of NO synthase (iNOS) also plays
Immunohistochemical localization of nitrotyrosine in the lung Figure 5
Immunohistochemical localization of nitrotyrosine in the lung. No positive staining was observed in the lung section 
for sham-treated mice (A). After bleomycin injection in iNOSWT mice, positive staining for nitrotyrosine (B) was localized 
mainly in nuclei of inflammatory cells. There was a marked reduction in the immunostaining in the lungs of bleomycin-treated 
iNOSKO mice (C) and in the lungs of bleomycin-treated iNOSWT mice which received GW274150 (D). Original magnifica-
tion: 150×. This figure is representative of at least 3 experiments performed on different experimental days.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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important role in various models of inflammation
[5,9,46]. Pharmacological inhibitors of NOS, and also
ablation of the gene for iNOS has been shown to reduce
the development of the inflammatory response [47-49].
In addition, various studies have point out that iNOS play
an important role in the pulmomary fibrosis induced by
bleomycin [50-52]. Therefore, some study have also dem-
onstrated that non-selective and partial selective iNOS
inhibitor like aminoguanidine exert beneficial effect
against lung injury induced by bleomycin [53-57]. How-
ever, frequently a misunderstanding is the definition of an
inhibitor as selective for, e.g. iNOS versus eNOS, and then
ignoring its non-selectivity for nNOS or completely dis-
tinct enzyme targets. An interesting example is aminogua-
nidine that is a partially selective for iNOS versus eNOS
[58], while the selectivity over nNOS is minimal. Moreo-
ver it has a wide range of other effects, inhibiting
advanced glycosylation end-product formation, diamine
oxidase and polyamine metabolism [59,60], catalase [61]
and having anti-oxidant effects [62,63]. For this reason
aminoguanidine should not be described as a selective
inhibitor.
Effect of genetic or pharmacological inhibition of iNOS on Thiobarbituric acid-reactant substances, a good indicator of lipid  peroxidation, in the lung Figure 6
Effect of genetic or pharmacological inhibition of iNOS on Thiobarbituric acid-reactant substances, a good 
indicator of lipid peroxidation, in the lung. Thiobarbituric acid-reactant substances levels in the lungs of bleomycin-
treated iNOSWT mice were significantly increased in comparison to sham-operated mice. The genetic or pharmacological 
inhibition of iNOS significantly reduced the bleomycin-induced increase in Thiobarbituric acid-reactant substances levels. Data 
are means ± s.e. means from 10 mice for each group. *p < 0.01 versus sham. °p < 0.01 represents significant reduction of the 
various parameters in the group in which iNOS was inhibited or absent.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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In contrast, GW274150 is a novel, potent and selective
inhibitor of iNOS activity and previous studies have dem-
onstrated its protective effect in organ injury in hemor-
rhagic shock, in renal ischemia and reperfusion and in a
model of collagen-induced arthritis [24-26]. This study
provides the first evidence of the protective role of
GW274150 in an experimental model of lung fibrosis.
Here we demonstrate that the lack of iNOS gene as well as
the pharmacological inhibition of iNOS (GW274150
treatment) reduces: i) the development of bleomycin-
induced lung injury, (ii) the infiltration of the lung with
inflammatory cells, (iii) the degree of nitrosative stress in
the lung and (iv) the mortality rate. All of these findings
support the view that NO plays an important role in the
degree of inflammation and lung fibrosis caused by bleo-
mycin in the mice. We report in the present study a reduc-
tion of the tissue damage in the lung of bleomycin-treated
iNOSKO mice as well as bleomycin-treated iNOSWT mice
which received the treatment with GW274150.
Two of the most recognized fibrosis markers, lung colla-
gen deposition and TGF-β 1 expression, were significantly
reduced in these animals. Evidence from animal models
and human studies suggests that TGF-β 1 plays a central
role in a variety of fibroproliferative disorders, including
pulmonary fibrosis. TGF-β 1 plays a critical role in the
pathogenesis of lung fibrosis through stimulation of col-
lagen and fibronectin production in fibroblasts [64], as
Effect of genetic or pharmacological inhibition of iNOS on body weight Figure 7
Effect of genetic or pharmacological inhibition of iNOS on body weight. Body weight was recorded immediately 
before bleomycin administration and daily for all the experimental period. The genetic or pharmacological inhibition of iNOS 
significantly prevents the loss of body weight. Data are means ± s.e. means from 10 mice for each group. *p < 0.01 represents 
significant reduction of the various parameters in the group in which iNOS was inhibited or absent.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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well as through inhibition of biosynthesis of proteases
that degrade the extracellular matrix [65]. TGF-β 1 pro-
motes wound healing [66] and its presence has been
shown to be increased in bleomycin -induced lung fibro-
sis [67,68] and particularly in lung macrophages [69]. In
addition it has been shown that during the course of
pulmonary fibrosis the increase of TGF-β 1 mRNA precede
the increase of type I and type III procollagen mRNAs The
secretion of biologically active TGF-β 1 by alveolar macro-
phages is transiently elevated in bleomycin -induced pul-
monary inflammation, whereas latent (L)-TGF-β 1
secretion remains elevated for a prolonged length of time
and it is probable that the extent of inflammation and
fibrosis in this model depends on the quantity of active
TGF-β 1 available [70].
In BAL of iNOSWT animals, that underwent bleomycin
instillation we observed, a strong increase of inflamma-
tory cells such as macrophages and neutrophils. This
could justify, at least in part, the significantly higher TGF-
β 1 expression and the increased lung collagen content in
these mice. Bleomycin-treated iNOSKO mice as well as
bleomycin-treated iNOSWT mice which received the treat-
ment with GW274150 showed both significantly reduced
TGF-β 1 expression as well as lung collagen deposition,
together with a significantly reduced inflammatory cells
Effect of genetic or pharmacological inhibition of iNOS on bleomycin-induced mortality Figure 8
Effect of genetic or pharmacological inhibition of iNOS on bleomycin-induced mortality. Survival is significantly 
improved in iNOSKO and iNOSWT GW274150-treated mice in comparison to the high mortality rate of the bleomycin-
treated iNOSWT mice. Data are means ± s.e. means from 20 mice for each group. *p < 0.01 represents significant reduction 
of the various parameters in the group in which iNOS was inhibited or absent.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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presence in the BAL. Furthermore we report in the present
study in the lung tissue of bleomycin-treated iNOSKO
mice as well as bleomycin-treated iNOSWT mice which
received the treatment with GW274150 a significant
reduction of leukocyte infiltration as assessed by the spe-
cific granulocyte enzyme MPO. Neutrophils recruited into
the tissue can contribute to tissue destruction by the pro-
duction of reactive oxygen metabolites, granule enzymes,
and cytokines that further amplify the inflammatory
response by their effects on macrophages and lym-
phocytes [71]. Furthermore, we found that the tissue dam-
age induced by bleomycin in vehicle-treated mice was
associated with an intense immunostaining of
nitrotyrosine formation also suggesting that a structural
alteration of the lung had occurred, most probably due to
the formation of highly reactive nitrogen-derivatives.
Recent evidence indicates, that bleomycin is a well-known
cause of intracellular oxidative stress, several findings in
this study suggest that extracellular oxidative stress may
also play a role in the pathogenesis of bleomycin-induced
lung injury [72,73]. Therefore, in this study we clearly
demonstrate that the genetic and pharmacological inhibi-
tion of iNOS prevent the formation of peroxynitrite.
Nitrotyrosine formation, along with its detection by
immunostaining, was initially proposed as a relatively
specific marker for the detection of the endogenous for-
Effect of genetic or pharmacological inhibition of iNOS on bleomycin-induced total and differential cellularity of bronchoalveo- lar lavage (BAL) Figure 9
Effect of genetic or pharmacological inhibition of iNOS on bleomycin-induced total and differential cellularity 
of bronchoalveolar lavage (BAL). (A) Total BAL cellularity for sham and bleomycin treated mice. (B) Differential cells 
counts for macrophages, lymphocytes, neutrophils and eosinophils per milliliter of BAL fluid are shown. Data, expressed as 
means ± s.e., are representative of 10 mice for each group. * p < 0.001 vs. sham, °p < 0.001 vs. bleomycin treated iNOSWT, # 
p < 0.001 vs. sham, ●  p < 0.001 vs. bleomycin treated iNOSWT, ◆  p < 0.05 vs. bleomycin treated iNOSWT.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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mation "footprint" of peroxynitrite [74]. There is, how-
ever, recent evidence that certain other reactions can also
induce tyrosine nitration; e.g., the reaction of nitrite with
hypoclorous acid and the reaction of myeloperoxidase
with hydrogen peroxide can lead to the formation of
nitrotyrosine [75]. Increased nitrotyrosine staining is con-
sidered, therefore, as an indication of "increased nitrative
stress" rather than a specific marker of the generation of
peroxynitrite. From the present data, we cannot determine
the mechanism of tyrosine nitration: inhibition of NOS
by NOS inhibitor would inhibit both NO formation (and
thus, reduce the generation of peroxynitrite) as well as it
would suppress nitrite formation (and thereby attenuate
the peroxidase dependent mechanisms of tyrosine nitra-
tion). Nevertheless, we can certainly conclude from the
current data that the absence of iNOS significantly
reduced tyrosine nitration in vivo.
Conclusion
In conclusion, this study demonstrates that the degree of
inflammation and fibrosis caused by injection of bleomy-
cin is significantly attenuated in iNOSKO mice as well as
in the iNOSWT mice treated with GW274150. These find-
ings support the view that the induction of iNOS contrib-
utes to the extension of inflammation in the model of
bleomycin-induced lung fibrosis used here. Finally, we
provide the first evidence that GW274150 causes a sub-
stantial reduction of lung fibrosis in the mice and our
Western blot analysis of TGF-β 1 expression in wild type (WT), iNOS-/-(KO) and GW274150-treated (GW) mice exposed to  vehicle (C) or bleomycin (bleo) for 7 days Figure 10
Western blot analysis of TGF-β 1 expression in wild type (WT), iNOS-/-(KO) and GW274150-treated (GW) 
mice exposed to vehicle (C) or bleomycin (bleo) for 7 days. Representative blots are reported in a. In b, data, normal-
ized for β -actin expression, represent mean the bleomycin induced TGF-β 1 percent increase of control groups (+/- SE) of 7 
independent experiments. *p < 0.05 and **p < 0.001 vs iNOSWT mice.Respiratory Research 2005, 6:58 http://respiratory-research.com/content/6/1/58
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findings suggest that interventions, which may reduce the
generation or the effects of iNOS, may be useful in condi-
tions associated with local or systemic inflammation.
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